Anton Kolomeyer, MD
Ophthalmology · Philadelphia, PANPI 1245573864
Payments from drug & device makers
Across 511 payments — averaging $694.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$129K
- Regeneron Healthcare Solutions, Inc.$67K
- Biogen$56K
- Genentech USA, Inc.$42K
- Alimera Sciences, Inc.$33K
- AbbVie$19K
- plus $10K from 17 others
Across 12 payments — averaging $923.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$11K
What the payments were for
- Consulting fees$54,69815%
- Speaking & faculty fees$265,02975%
- Travel & lodging$19,0485%
- Food & beverage$15,9024%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 105 | $128,736 |
| Regeneron Healthcare Solutions, Inc. | 84 | $66,570 |
| Biogen | 43 | $55,719 |
| Genentech USA, Inc. | 60 | $42,484 |
| Alimera Sciences, Inc. | 81 | $32,515 |
| AbbVie(2 entities) | 58 | $18,815 |
| Apellis Pharmaceuticals, Inc. | 17 | $3,978 |
| Genentech, Inc. | 2 | $3,960 |
| Coherus Oncology, Inc. | 13 | $411 |
| Novartis | 10 | $342 |
| Sight Sciences, Inc. | 3 | $280 |
| ANI Pharmaceuticals, Inc. | 16 | $252 |
| Eyepoint US, Inc. | 4 | $218 |
| Aerie Pharmaceuticals, Inc. | 1 | $125 |
| Sandoz | 4 | $123 |
| Tarsus Pharmaceuticals, Inc. | 2 | $36 |
| Notal Vision, Inc. | 1 | $34 |
| Bausch & Lomb Americas Inc. | 2 | $31 |
| Harrow Eye, LLC | 1 | $25 |
| Dompe US, Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Oyster Point Pharma, Inc. | 1 | $14 |
| Kala Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$354,716 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 191 | $9,548 |
| Latanoprost | 168 | $2,441 |
| Atropine Sulfate | 45 | $1,952 |
| Difluprednate | 19 | $1,574 |
| Ketorolac Tromethamine | 47 | $1,049 |
| Ciprofloxacin Hcl | 49 | $813 |
| Brimonidine Tartrate | 57 | $738 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 56 | $700 |
| Dorzolamide Hcl | 20 | $328 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 22 | $253 |
| Timolol Maleate | 11 | $132 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Philadelphia
- Julia HallerPhiladelphia$1.5M
- Jonathan MyersPhiladelphia$660K
- Beeran MeghparaPhiladelphia$496K
- Cesar BricenoPhiladelphia$487K
- Mark BlecherPhiladelphia$357K
- Leslie KatzPhiladelphia$159K
- Durga BorkarPhiladelphia$150K
- Bennie JengPhiladelphia$142K
- Rachel NiknamPhiladelphia$142K
- Joseph MarkoffPhiladelphia$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.